Dr. Michael Rome joined Foresite Capital in 2016 and co-leads the therapeutics investing practice. Michael is a board director at Kinnate Biopharma, Pharvaris, and Remix Therapeutics, with board observer roles (past and present) at Turning Point Therapeutics, Maze Therapeutics, PACT Pharma, and Nurix Therapeutics. Michael served as Vice President for Foresite Development Corporation (FSDC) and has led investments in several public companies across the portfolio. Prior to Foresite Capital, he was an analyst at DAFNA Capital Management, covering and formulating investment ideas for small/mid-cap biotech companies.
Michael previously worked in early-stage drug development for an academic start-up out of the California NanoSystems Institute at UCLA. He received his Ph.D. in Biochemistry from Caltech as an NSF graduate research fellow, and his B.S. in Molecular, Cell and Developmental Biology from UCLA. He has more than 12 years of experience as a research scientist and has authored numerous publications in biomedical research journals.